



Express Mail No.: EV475142618US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Zeldis

Confirmation No.: 9771

Application No.: 10/534,325

Group Art Unit: 1614

Filed: May 5, 2005

Examiner: Gembah, Shirley V

For: METHODS AND COMPOSITIONS
USING SELECTIVE CYTOKINE
INHIBITORY DRUGS FOR THE
TREATMENT AND
MANAGEMENT OF CANCERS
AND OTHER DISEASES

Attorney Docket No.: 9516-207-999

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicant hereby invite the Examiner's attention to references **C62** to **C65** listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references **C62** to **C65** are provided herewith.


Identification of the listed references is not meant to be construed as an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application. The cited references were cited by the European Patent Office in the counterpart European application on April 13, 2006.

Applicant respectfully requests that the Examiner review the foregoing reference and that the reference be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), Applicant estimates that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: May 18, 2006

	(Reg. No.)
By: Yeahsil Moon	35,203
For: Anthony M. Insogna	52,042
JONES DAY	
222 East 41 st Street	
New York, New York 10017-6702	
(212) 326-3939	

Enclosures



Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.

9516-207-999

APPLICATION NO.

10/534,325

APPLICANT:

Zeldis

FILING DATE:

May 5, 2005

ART UNIT: CONF. NO.:

1614

9771

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS*	DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS*	Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
					YES	NO

NON PATENT LITERATURE DOCUMENTS (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published., etc.)

EXAMINER'S INITIALS*		
	C62	DATABASE NLDB XP002371400 retrieved from STN. Database accession no. 2002:87776, & BIOWORLD Today, Vol. 13, No. 68. April 10, 2002.
	C63	DATABASE PHIN "Celgene moving beyond Thalidomid" XP002371401 retrieved from STN. Database accession no. 2001:12958, & SCRIP (Newsletter), No. 2657 p. 12. July 4, 2001.
	C64	LI et al., "Tumor angiogenesis: Molecular pathology, therapeutic targeting, and imaging," 2000, Academic Radiology, 7(10):800-811.
	C65	OLIVER et al., "Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis," 1999, Clinical and Experimental Immunology, 118(2):315-321.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.